Breakthrough invasive candidiasis in pediatric patient with Ewing’s sarcoma: dinical case report and literature review

We presented clinical case of invasive candidiasis in 13 years old girl with Ewing's sarcoma during intensive treatment with combined chemotherapy according EWING 2008 protocol. The most significant risk factors were recurrent chemotherapy induced neutropenia gr IV, multifocal Candida colonization, prolonged central venous catheter use, combined antibiotic therapy in the previous >10 days, parenteral nutrition. In spite of provided prophylaxis and antifungal therapy patient died because of progression of invasive candidiasis. We analyzed literature data on frequency of invasive candidiasis in children with Ewing's sarcoma and cases of breakthrough candidiasis in pediatric malignancies.

1. Craft A.W. Childhood cancer - mainly curable so where next? Acta Paediatr 2000;89(4):386-92. DOI: 10.1080/080352500750028041.

2. Alexander S., Pole J., Gibson P. et al. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol 2015;16(16):e604—10. DOI: 10.1016/S1470-2045(15)00197-7.

3. Groll A., Castagnola E., Cesaro S. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in pediatric patients with cancer or allogeneic hae-mopoietic stem-cell transplantation. Lancet Oncol 2014;15(8):e327-40. DOI: 10.1016/S1470-2045(14)70017-8.

4. Zirkel J., Klinker H., Kuhn A. et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med My-col 2012;50(1):50—5. DOI: 10.3109/13693786.2011.587211.

5. Adamkiewicz-Drozynska E., Bien E., Ploszynska A. Invasive fungal infection in a child with Ewing’s sarcoma. Onco Rev 2017;1(25):A38-43. DOI: 10.5604/01.3001.0009.7393.

6. Dinikina Yu.V., Shadrivova O.V., Belogurova M.B. et al. Invasive aspergillosis in children and adolescents with solid tumors: clinical cases and registry analysis. Onkogema-tologiya = Oncohematology 2019;14(1):40-8. (In Russ.).

7. Choi Y.B., Yi E.S., Kang J.M. et al. Infectious complications during tandem high-dose chemotherapy and autologous stem cell transplantation for children with high-risk or recurrent solid tumors. PLoS ONE 2016;11(9):e0162178. DOI: 10.1371/journal.pone.0162178.

8. Zaoutis T.E., Argon J., Chu J. et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41(9):1232—9. DOI: 10.1086/496922.

9. Zaoutis T.E., Prasad P.A., Localio A.R. et al. Risk factors and predictors for can-didemia in pediatric intensive care unit patients: Implications for prevention. Clin Infect Dis 2010;51(5):e38—45. DOI: 10.1086/655698.

10. Cornely O.A., Hoenigl M., Lass-Florl C. et al. Defining breakthrough invasive fungal infection — position paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). Mycoses 2019;62(9):716-29. DOI: 10.1111/myc.12960.

11. De Pauw B., Walsh T.J., Donnelly J.P. et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813—21. DOI: 10.1086/588660.

12. Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy. Clinical recommendations “Determination of microorganisms sensitivity to antimicrobial agents”, 2018-03 version. 206 p. (In Russ.).

13. Kaatsh P., Strothotte J., Becker C. et al. Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival. Acta Oncol 2016;55(9—10):1145—51. DOI: 10.1080/0284186X.2016.1195509.

14. Czyzewski K., Galazka P., Zalas-Wiecek P. et al. Infectious complications in children with malignant bone tumors: a multicenter nationwide study. Infect Drug Resist 2019;12:1471-80. DOI: 10.2147/IDR.S199657.

15. Yera H., Poulain D., Lefebvre A. et al. Polymicrobial candidaemia revealed by peripheral blood smear and chromogenic medium. J Clin Pathol 2004;57(2):196— 8. DOI: 10.1136/jcp.2003.9340.

16. Kim S.Y., Lim J.S., Kim D.H. et al. Candida tropicalis arthritis of the elbow in a patient with Ewing’s sarcoma that successfully responded to itraconazole. Korean J Pediatr 2011;54(9):385—8. DOI: 10.3345/kjp.2011.54.9.385.

17. Ridola V., Chachaty E., Raimondo G. et al. Candida infections in children treated with conventional chemotherapy for solid tumors (transplant recipients excluded): The Institut Gustave Roussy Pediatrics Department experience. Pediatr Blood Cancer 2004;42(4):332—7. DOI: 10.1002/pbc.10452.

18. Barlett A., Cann M., Yeoh D. et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. Pedi-atr Blood Cancer 2019;66(4):e27564. DOI: 10.1002/pbc.27564.

19. Styczynski J., Czyzewski K., Wysocki M. et al. Increased risk of infections and infection-related mortality in children undergoing hematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicenter nationwide study. Clin Microbiol Infect 2016;22(2):179.e1 —10. DOI: 10.1016/j.cmi.2015.10.017.

20. El-Mahallawy H.A., Attia I., Ali-El-Din N.H. et al. A prospective study on fungal infection in children with cancer. J Med Microbiol 2002;51(7):601 — 5. DOI: 10.1099/0022-1317-51-7-601.

21. Celebi S., Hacimustafaoglu M., Oz-demir O., Ozkaya G. Nosocomial candi-daemia in children: results of a 9-year study. Mycoses 2008;51(3):248—57. DOI: 10.1111/j.1439 0507.2007.01464.x.

22. Alberth M., Majoros L., Kovalecz G. et al. Significance of oral Candida infections in children with cancer. Pathol Oncol Res 2006;12(4):237—41. DOI: PAOR.2006.12.4.0237.

23. Pana Z., Roilides E., Warris A. et al. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc 2017;6(Suppl 1):S3—11. DOI: 10.1093/jpids/pix046.

24. Hawkshead J.J. 3rd, Van Dyke R.B., Hassig S.E. et al. Species-based comparison of disease severity and risk factors for disseminated Candida infections in pediatric patients. Infect Drug Resist 2016;9:59-70. DOI: 10.2147/IDR.S102490.

25. Mor M., Gilad G., Kornreich L. et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011;56(7):1092—7. DOI: 10.1002/pbc.23005.

26. Mullen C., Ei-Baki H., Samir H. et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 2003;11(5):321 — 5. DOI: 10.1007/s00520-003-0453-9.

27. Doring M., Eikemeier M., Cabanillas Stanchi K. et al. Antifungal prophylaxis with posaconazole vs. fluconazole or intraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis 2015;34(6):1189—200. DOI: 10.1007/s10096-015-2340-y.

28. Carr A., Berhe M., Colley P. Risk factors for Candidemia as Compared with patients with negative blood cultures placed on empiric micafungin. OFID, Poster abstracts 2017;4(1):S79.

29. Hirano R., Sakamoto Y., Kitazawa J. et al. Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan. Infect Drug Resist 2018;11:821-33. DOI: 10.2147/IDR. S156633.

30. Robenshtok E., Gafter-Gvili A., Goldberg E. et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systemic review and meta-analysis. J Clin Oncol 2007;25(34):5471 — 89. DOI: 10.1200/JCO.2007.12.3851.

31. Hope W., Castagnola E., Groll A. et al. ESCMMID* guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18(Suppl 7):38—52. DOI: 10.1111/1469-0691.12040.

32. Pfeiffer C., Garcia-Effron G., Zaas A. et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010;48(7):2373—80. DOI:10.1128/JCM.02390-09.

33. Mehta P., Vinks A., Filipovich A. et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010;16:1458—62. DOI: 10.1016/j.bbmt.2010.05.002.

34. Markova I.V., Rogacheva Yu.A., Popova M.O. and others. Invasive candidiasis/candidaemia in children after hematopoietic stem cell transplantation. Voprosy gematologii/ onkologii i immunopatologii v pediatrii = Questions of hematology/oncology and immunopathology in pediatrics 2019;18(2):53—8. (In Russ.).

35. Muro M.D., Motta F., Burger M. et al. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients. J Clin Mycol 2012;50(11):3783— 5. DOI: 10.1128/JCM.01136-12.

36. Pappas P., Kauffman C., Andes D. et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1 — 50. DOI: 10.1093/cid/civ933.

37. Lai M.Y., Hsu J.F., Chu S.M. et al. Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes. Future Microbiol 2017:695—705. DOI: 10.2217/fmb-2016-0223.

38. Nucci M., Colombo A.L., Spector N. Breakthrough candidemia in neutropenic patients. Clin Infect Dis 1997;24:275—6.

39. Chong Y., Shimoda S., Yakushiji H. et al. Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies. J Infect Chemother 2012. DOI: 10.1007/s10156-012-0412-9.

40. Park M., Park J., Song D. et al. First case of echinocandin-resistant Candida albicans in Korea. Ann Lab Med 2017;37(6):556—8. DOI: 10.3343/alm.2017.37.6.556.

41. Fraser M., Borman A., Thorn R., Lawrance L. Resistance to echinocan-din antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment. Medical Mycology 2019;0:1—8. DOI: 10.1093/mmy/myz053.

42. Funaki T., Miyairi I. Breakthrough candidemia in children on micafungin. Pediatr Infect Dis J 2018;37(12): 1258—60. DOI: 10.1097/INF.0000000000002020.

43. Pasqualotto A.C., Nedel W.L., Machado T.S., Severo L.C. Risk factors and outcome for nosocomial breakthrough candidemia. J Infect 2006;52:216—22. DOI: 10.1016/j.jinf.2005.04.020.

44. Breda G., Tuon F., Meis J. et al. Breakthrough candidemia after the introduction of broad spectrum antifungal agents: a 5-year retrospective study. Medical Mycology 2017;0:1 —10. DOI: 10.1093/mmy/myx077.

45. Weinberger M., Leibovici L., Perez S. et al. Characteristics of candidaemia with Candida-albicans compared with nonalbicans Candida species and predictors of mortality. J Hosp Infect 2005;61(2):146 — 54. DOI: 10.1016/j.jhin.2005.02.009.

46. Krcmery V., Laho L., Huttova M. et al. Aetiology, antifungal susceptibility, risk factors and outcome in 201 fun-gaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol 2002;51:110—6. DOI: 10.1099/0022-1317-51-2-110.